MARKET

HRTX

HRTX

Heron Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.48
+0.92
+5.24%
Pre Market: 18.79 +0.31 +1.68% 04:11 05/12 EDT
OPEN
17.38
PREV CLOSE
17.56
HIGH
18.53
LOW
17.26
VOLUME
100
TURNOVER
--
52 WEEK HIGH
22.40
52 WEEK LOW
12.52
MARKET CAP
1.69B
P/E (TTM)
-7.3820
1D
5D
1M
3M
1Y
5Y
Benzinga Pro's Top 5 Stocks To Watch For Tuesday, May 11, 2021: GLD, AMC, COIN, HRTX, FLXN
Today's 5 Stock Ideas SPDR Gold Trust (GLD) - Despite bearish sentiment in the stock market by retail investors, stocks (as measured by the S&P 500 index) were down only about 2% from all-time highs. The
Benzinga · 19h ago
64 Biggest Movers From Yesterday
Gainers InnSuites Hospitality Trust (NYSE: IHT) shares jumped 82.6% to settle at $6.39 on Monday.
Benzinga · 23h ago
Heron Stock Trading Higher After Q1 Earnings, Ahead Of HTX-011 Decision Scheduled This Week
Benzinga · 1d ago
40 Stocks Moving In Monday's Mid-Day Session
Gainers Protagenic Therapeutics, Inc. (NASDAQ: PTIX) shares jumped 64.2% to $3.4962 on above-average news.
Benzinga · 1d ago
Heron Therapeutics climbs on management comments over upcoming milestone
Heron Therapeutics (HRTX) is trading sharply higher despite its lower-than-expected financial results for Q1 2021. The management remarks over an impending FDA decision for the company’s investigational non-opioid analgesic appear to have
Seekingalpha · 1d ago
Heron Therapeutics (HRTX) Reports Q1 Loss, Misses Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -1.75% and -25.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 1d ago
Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2021 and Highlights Recent Corporate Updates
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results...
PR Newswire · 1d ago
Heron Therapeutics EPS misses by $0.03, misses on revenue
Heron Therapeutics (HRTX): GAAP EPS of -$0.58 misses by $0.03.Revenue of $20M (-21.3% Y/Y) misses by $5.73M.Cash, cash equivalents and short-term investments of $166.5MHeron expects that its current cash, cash equivalents
Seekingalpha · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HRTX. Analyze the recent business situations of Heron Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HRTX stock price target is 33.89 with a high estimate of 70.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 300
Institutional Holdings: 110.51M
% Owned: 120.55%
Shares Outstanding: 91.67M
TypeInstitutionsShares
Increased
54
7.92M
New
22
1.26M
Decreased
63
2.44M
Sold Out
19
6.96M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.34%
Pharmaceuticals & Medical Research
-0.29%
Key Executives
Chairman/Chief Executive Officer/Director
Barry Quart
President
John Poyhonen
Chief Operating Officer/Executive Vice President
David Szekeres
Executive Vice President/Director
Kimberly Manhard
Senior Vice President/Chief Scientific Officer
Thomas Ottoboni
Senior Vice President
Anita Gupta
Senior Vice President
Michael Mathews
Chief Accounting Officer/Vice President
Lisa Peraza
Vice President/Director of Human Resources
Sean Ristine
Vice President
John Arthur
Other
Christopher Storgard
Lead Director/Independent Director
Craig Johnson
Director
Steve Davis
Independent Director
Stephen Davis
Independent Director
Christian Waage
No Data
  • All
  • Financials
  • Insiders
More
About HRTX
Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.

Webull offers kinds of Heron Therapeutics Inc stock information, including NASDAQ:HRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HRTX stock methods without spending real money on the virtual paper trading platform.